Coronavirus Breaking News

The coronavirus disease COVID-19 is currently reaching pandemic levels in various countries.

Jun 7, 2021 • 11:12 am CDT

Massachusetts-based Moderna, Inc. and Medison Pharma announced a new agreement to commercialize the experimental Moderna COVID-19 Vaccine across Central Eastern Europe and Israel.

"We are excited to partner with Moderna in 20 markets, covering over 175 million lives across the entire Central Eastern Europe region and in Israel,” commented Meir Jakobsohn, Founder and CEO of Switzerland-based Medison Pharma.

“Moderna’s breakthrough vaccine and Medison’s international commercialization platform for highly innovative treatments makes our partnership a natural fit.”

This agreement covers the following countries: Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia and Herzegovina, Kosovo, North Macedonia, Montenegro, and Israel.

The U.S. FDA issued Authorization for the Moderna vaccine in December 2020 but has not Authorized it as of June 7, 2021.

Jun 5, 2021 • 12:34 pm CDT

On June 5, 2021, WalesOnline reported that First Minister Mark Drakeford described how he believed people in Wales are very happy to continue following social distancing guidelines of 2m.

And social distancing will likely remain in Wales for the rest of 2021

Speaking at a press conference on Friday, Mr. Drakeford described social distancing as the "strongest defense" against the virus, adding that he does not believe people in Wales want to see it gone.

The government of Wales published the updated rules that are effective on June 7, 2021. These rules include:

  • Regulated events allowed outdoors with up to 10,000 people seated or up to 4,000 people standing (subject to risk assessment)
  • Extended households can be formed between 3 households
  • Up to 30 people can meet in any outdoor area, including private gardens, public spaces, and outdoor regulated premises such as cafes, restaurants, and bars.

In England, the social distancing rules were changed on May 17, 2021.

The new guidance from the UK government 'on meeting friends and family emphasizes personal responsibility rather than government rules. Instead of instructing you to stay 2m apart from anyone you don’t live with, you are encouraged to exercise caution and consider the guidance on risks associated with COVID-19 and actions you can take to help keep you and your loved ones safe.'

Jun 4, 2021 • 12:44 pm CDT

With more than 169 million people in the USA vaccinated against COVID-19 with one of three U.S. FDA Authorized vaccines, Breakthrough Cases confirmed by the U.S. CDC continue to increase.

As of June 1, 2021, the CDC received reports from 47 U.S. states and territories of 3,016 patients with COVID-19 vaccine Breakthrough infections who were hospitalized or died.

And about 79% of the Breakthrough Cases were seniors (65 yr).

In total, there have been 2,854 hospitalized or 535 fatal cases confirmed. The CDC reported 16% of 535 fatal cases were reported as asymptomatic or not related to COVID-19.

As of May 1, 2021, the CDC transitioned from monitoring all reported vaccine Breakthrough Cases to identify and investigate only hospitalized or fatal cases due to any cause. This shift maximizes the quality of the data collected on cases of greatest clinical and public health importance.

Previous data on all vaccine Breakthrough Cases reported to CDC from January–April 2021 are available at this CDC link.

CDC developed a national COVID-19 vaccine breakthrough REDCap database where designated state health department investigators can enter, store, and manage data for cases in their jurisdiction. State health departments have full access to data for cases reported from their jurisdiction. Ultimately, CDC will use the National Notifiable Diseases Surveillance System to identify vaccine breakthrough cases.

Medical Review by
Jun 4, 2021 • 8:05 am CDT

A research team from the University of Birmingham found Dental care professionals (DCPs) in England were at heightened occupational risk for SARS-CoV-2 virus infection early in the COVID-19 pandemic, according to an observational study published in the Journal of Dental Research on June 2, 2021.

The baseline seroprevalence of DCPs was 16.3%, compared to estimates in the regional population of up to 7%.

The only virus-reinfected DCPs were those without a detectable anti-spike protein immunoglobulin G response, either because they had undetectable IgG concentrations at baseline or because their IgG response dwindled over time.

These researchers stated, 'Consistent with other studies, we demonstrate that natural infection with SARS-CoV-2 is generally associated with robust and durable serological responses' (Wajnberg et al. 2020; Dan et al. 2021).'

'Furthermore, in this community-based cohort of DCPs, we corroborate the hospital-based studies of Lumley et al. (2020) and Hanrath et al. (2020) in demonstrating that seropositivity arising from natural infection is associated with longitudinal protection from reinfection with SARS-CoV-2.'

In the USA, the American Dental Association (ADA) issued guidance on May 19, 2021, to help dentists answer questions about new recommendations from the U.S. Centers for Disease Control and Prevention (CDC) regarding mask use for fully vaccinated people.

The CDC recommendations state, “Although screening for symptoms will not identify asymptomatic or pre-symptomatic individuals with SARS-CoV-2 virus infection, symptom screening remains an important strategy to identify those who could have COVID-19 so that appropriate precautions can be implemented.”

Medical Review by
Jun 3, 2021 • 6:56 pm CDT

The JAMA launched an Orginal Investigation among residents and staff of skilled nursing and assisted living facilities with a high risk of SARS-CoV-2 exposure to discover what is the effect of bamlanivimab on the incidence of COVID-19?

This JAMA investigation concluded on June 3, 2021, 'Among residents and staff in skilled nursing and assisted living facilities, treatment during August-November 2020 with bamlanivimab monotherapy reduced the incidence of COVID-19 infection.'

This randomized phase 3 clinical trial included 966 participants and staff at US skilled nursing and assisted living facilities with at least 1 confirmed SARS-CoV-2 index case and who were negative at baseline for SARS-CoV-2 infection and serology, enrolled from August to November 2020.

The incidence of COVID-19 infection among those treated with bamlanivimab vs. placebo was 8.5% vs. 15.2%, respectively, a statistically significant difference.

All COVID-19–related deaths reported during this trial occurred among participants in the placebo group.

This potential protective effect of bamlanivimab in reducing mortality could be due to fewer participants acquiring SARS-CoV-2 infections and lower viral loads among those infected since persistently high viral load has previously been identified as a risk factor for worse outcomes.

'The results presented herein primarily represent validation of the use of neutralizing monoclonal antibodies as protective passive immunotherapy against COVID-19, with potential clinical relevance for antibody therapies in continued distribution,' concluded these researchers.

Eli Lilly's Bamlanivimab (LY-CoV555) is an investigational neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein SARS-CoV-2 coronavirus, designed to block viral attachment and entry into human cells.

Medical Review by
Jun 2, 2021 • 12:27 pm CDT

The Moscow-based Russian Direct Investment Fund (RDIF) announced data from the Ministry of Health of the province of Buenos Aires, Argentina, on June 2, 2021, which confirmed the efficiency of the Sputnik Light vaccine at the level of 78.6-83.7% when vaccinating the elderly.

According to the analysis of data, more than 186 thousand people aged 60 to 79 years, more than 40 thousand of whom received an injection of the single-dose "Sputnik Light" vaccine during the mass vaccination of the population.

The data showed SARS-CoV-2 virus incidence from 21 to 40 days after receiving one vaccine injection was only 0.446%. The incidence among the adult unvaccinated population for the same period was 2.74%.

The data adjusted for age, gender, and several other parameters of vaccinated and unvaccinated people showed comparable efficacy of the Sputnik Light vaccine at the level of 78.6%.

Kirill Dmitriev, CEO of the RDIF, said in a press statement, “The publication of independent data in the province of Buenos Aires confirms the high effectiveness of the Russian vaccine for senior citizens who are at high risk."

"As follows from the report of the Ministry of Health of the province, vaccination with Sputnik Light, which is the first component of the Sputnik V vaccine, can significantly reduce the number of cases and the number of hospitalizations. We plan to continue close contact with colleagues in Argentina to study further the data on the use of the Russian vaccine."

Sputnik Light is the first component (recombinant human adenovirus 26 serotype (rAd26) of the two-dose Sputnik V vaccine. The Sputnik Light vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold.

Medical Review by
Jun 2, 2021 • 8:07 am CDT

The World Health Organization (WHO) announced on May 31, 2021, Greek alphabet labels for the variants of the SARS-CoV-2 beta coronavirus that causes COVID-19.

All viruses, including SARS-CoV-2, change over time, says the WHO.

Most changes have little to no impact on the virus’s properties. However, some changes may affect the virus’s properties, such as how easily it spreads, the associated disease severity, or the performance of vaccines, therapeutic medicines, diagnostic tools, or other public health and social measures.

WHO stated it would assign labels for those variants that are designated as Variants of Interest or Variants of Concern by WHO.

These labels do not replace existing scientific names, conveying important scientific information, and will continue to be used in research.

Medical Review by
Jun 1, 2021 • 3:08 pm CDT

The Tehran Times reported the Soberana-02 COVID-19 vaccine would complete clinical trials by mid-June 2021 after administering it to 24,000 Iranians. The two first phases of the human clinical trial have been conducted in Cuba.

Developed by Cuba's Finlay Vaccine Institute and Pasteur Institute of Iran, the vaccine is a conjugate vaccine with two injectable doses. It consists of the receptor-binding domain of the SARS-CoV-2 spike protein conjugated chemically to tetanus toxoid.

In Iran, the study was performed on a population of 18 to 80 years in seven provinces and eight cities across the country, Alireza Biglari, director of the Pasture Institute of Iran, stated. He expressed hope to analyze the preliminary results in late June to obtain a license for mass production.

He expressed hope to start vaccinating Iran's population by late September 2021.

Jun 1, 2021 • 11:53 am CDT

The US Transportation Security Administration (TSA) reported airport security passenger screening volume remained about 25% less than before the COVID-19 pandemic began in 2019.

During the end of May 2021, including the Memorial Day weekend, the TSA's average number of daily screened travelers was about 1.8 million people. This compares with May 2019's volume of 2.4 million.

The peak day was recorded on May 28, 2021.

However, compared to May 2020's average passenger volume of less than 320,000 per day, it looks like the airline travel industry is on the road to recovery!

As of June 1, 2021, the U.S. CDC and State Department continue to discourage both domestic and international air travel.

May 31, 2021 • 10:38 am CDT

The government of Canada updated its travel policy, saying, 'We understand that you're arriving under difficult circumstances, but all travelers entering Canada must follow testing and quarantine requirements. This is to keep everyone safe, particularly given the new COVID-19 variants in Canada and around the world.'

However, Canadians returning after a compassionate visit abroad now have an option.

'If you're a resident of Canada flying home, you can now apply for an exemption from the mandatory hotel stopover.'

'We recommend that you submit your application for exemption before you leave Canada for compassionate reasons. Applications will not be processed upon arrival in Canada.'

Canada's Chief Public Health Officer of Canada is in close contact with provincial and territorial Chief Medical Officers of Health to ensure that any cases of COVID-19 occurring in Canada continue to be rapidly identified and managed to protect Canadians' health.

On May 30, 2021, Canada reported (34) additional fatalities related to COVID-19. The majority of COVID-19 cases have been confirmed in Ontario.

Medical Review by
May 30, 2021 • 1:28 pm CDT

The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) announced on May 29, 2021, the emergency use approval for the GSK Sotrovimab (Vir-7831) treatment.

GSK's Sotrovimab (VIR-7831, GSK4182136) is a fully human anti-SARS-CoV-2 monoclonal antibody with the potential to neutralize the SARS-CoV-2 coronavirus in vitro, kill infected cells, provide a high barrier to resistance, and achieve high concentrations in the lungs.

The UAE authorized Sotrovimab to treat patients aged 12 years or older with mild to moderate COVID-19 disease who are at risk of progression to hospitalization or death. In pre-clinical studies, Sotrovimab has demonstrated effectiveness as a monotherapy against widely circulating variants of the disease.

HE AbdulRahman bin Mohamad Al Owais, MoHAP, said in a press release, “The new medicine will greatly contribute to speeding up the recovery of patients, reducing Covid-19-related deaths and hospitalization period in intensive care units."

"It will also support the country’s efforts being made to conduct Covid-19 tests and administer vaccines, retaining its leading position among the world's foremost countries, dealing efficiently with the Covid-19 pandemic,” the minister said.

Additionally, the MoHAP announced on the 29th that it conducted 204,487 additional COVID-19 tests over the past 24 hours.

In a statement, the Ministry stressed its aim to continue expanding the nationwide testing scope to facilitate the early detection of coronavirus cases and carry out the necessary treatment. As part of its intensified testing campaign, MoHAP announced 1,812 new coronavirus cases, bringing the total number of recorded cases in the UAE to 567,263.

According to the Ministry, the infected individuals are from various nationalities, are in a stable condition, and receiving the necessary care.

The MoHAP also confirmed 5 deaths due to COVID-19 complications, bringing the total number of deaths in the country to 1,673 during the COVID-19 pandemic.

May 30, 2021 • 12:46 pm CDT

A spokesperson for the Central Epidemic Command Center (CECC) in Taiwan announced on May 30, 2021, the Taiwan Centers for Disease Control had signed contracts with Medigen Vaccine Biologics Corp. and United Biomedical to buy ten million COVID-19 vaccine doses from each, reported CNA.

Chuang Jen-hsiang (莊人祥) informed local reporters that the vaccines developed by Medigen and United Biomedical are still in second-stage clinical trials.

United Biomedical began second-stage clinical trials for the vaccine in January, and over 4,000 participants have received the required two doses to date, a company spokesperson told CNA.

The companies have said they plan to apply in June 2021 for emergency use authorization.

During 2021, Taiwan had received 726,600 doses of AstraZeneca and 150,000 doses of Moderna. A total of 378,277 people have received their first COVID-19 shots, according to the latest CECC data.

Additionally, media reported the CECC indicated 'there are no immediate plans to impose a full lockdown in Taiwan, although some cities and counties have been carrying out computerized drills to prepare for such an eventuality.'

As of May 19, 2021, the U.S. CDC issued a Level 1 Travel Alert, which stated, 'If you travel to Taiwan, get fully vaccinated before travel.'

May 30, 2021 • 6:43 am CDT

As of May 19, 2021, the United Kingdom's Medicines & Healthcare Regulatory Agency (MHRA) had received 382 Yellow Card reports of suspected adverse drug reactions (ADR) from people who received the Pfizer-BioNTech COVID-19 vaccine (Comirnaty) in which the patient died shortly after vaccination.

Furthermore, there were 806 reports for the COVID-19 Vaccine AstraZeneca (Vaxzevria) and 4 for the COVID-19 Vaccine Moderna.

The majority of these Yellow Card reports in the UK were in older people or people with underlying illnesses.

The MHRA is responsible for continuously monitoring the safety of all medicines and vaccines once they are approved for use.

The dedicated Coronavirus Yellow Card reporting site was launched in May 2020 specifically for medicines and medical devices used in COVID-19, as well as COVID-19 vaccines when authorized.

Visit Coronavirus (COVID-19): what you need to do to learn about the UK government's response to the coronavirus pandemic.

May 28, 2021 • 2:14 pm CDT

COVID-19 cases and deaths in the United States have dropped to their lowest levels in nearly a year, reported the US Centers for Disease Control and Prevention (CDC) on May 28, 2021.

However, certain medical conditions can increase the risk of being becoming severely ill due to COVID-19.

From March 1, 2020, through March 31, 2021, data shows that about 91% of adults with a laboratory-confirmed COVID-19-associated hospitalization have an underlying medical condition.

The most common underlying medical conditions include obesity (48.6%), metabolic disease including diabetes (43.9%), and cardiovascular disease (36.5%).

Additionally, among children ages 17 years and younger with a COVID-19-associated hospitalization, more than half have at least one underlying medical condition; the two most common are obesity (34.2%) and asthma (13.2%).

The CDC added 'As you make plans this summer, consider adding “visit my doctor” back to your list of things to do. Getting regular health care, routine screenings, and vaccinations can help prevent serious health problems, save money, and lead to better health.'

'If you’ve delayed medical care during the pandemic, now is the best time to see your doctor or healthcare provider.'

May 28, 2021 • 11:13 am CDT

The European Medicines Agency (EMA) announced on May 28, 2021, the Human Medicines Committee (CHMP) has recommended granting an extension of indication for the COVID-19 vaccine Comirnaty (BioNTech-Pfizer) to include use in children aged 12 to 15. The vaccine is already approved for use in adults and adolescents aged 16 and above.

The CHMP noted that the trial could not have detected rare side effects due to the limited number of children included in the study.

The committee also noted that EMA’s safety committee is currently assessing very rare cases of myocarditis and pericarditis after vaccination with Comirnaty, mainly in people under 30 years of age. Currently, there is no indication that these cases are due to the vaccine, and EMA is closely monitoring this issue.

Despite this uncertainty, the CHMP considered that the benefits of Comirnaty in children aged 12 to 15 outweigh the risks, particularly in children with conditions that increase the risk of severe COVID-19.

The safety and efficacy of the vaccine in both children and adults will continue to be monitored closely as it is used in vaccination campaigns across the Member States, through the EU pharmacovigilance system, and ongoing and additional studies by the company and by European authorities.

The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines for the benefit of public and animal health in the European Union.

Medical Review by